The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

A recent online survey by Leger, commissioned by Eisai Limited Canada, has revealed troubling statistics about sleep in ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

A recent online survey by Leger, commissioned by Eisai Limited (Canada), reveals alarming statistics about our sleep in ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

The green revolution is here!Most wellness articles about trying a new wake-up beverage start with some version of “I’ve ...

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

The extent of the sleep problems reported by Quebecers in the survey is not specified. To consider a person to have chronic ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

EcoNaviSta, Inc. has announced its board’s decision to support and recommend a tender offer by Eisai Co., Ltd. for its shares, which aims to make EcoNaviSta a wholly-owned subsidiary of Eisai. This ...